Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
1
20%
Ph phase_3
3
60%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

withdrawn120%
terminated120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

CEUS Evaluation of Hypoxic Ischemic Injury

NCT03549520
terminatedphase_3

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

NCT03549507
completedphase_3

Contrast Enhanced Ultrasound in COVID-19

NCT04640038
completedphase_2

The Role of Contrast Enhanced Ultrasound in Appendicitis

NCT03687502
withdrawnphase_1

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

NCT03295656

Clinical Trials (5)

Showing 5 of 5 trials
NCT03549520Phase 3

CEUS Evaluation of Hypoxic Ischemic Injury

Completed
NCT03549507Phase 3

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

Terminated
NCT04640038Phase 3

Contrast Enhanced Ultrasound in COVID-19

Completed
NCT03687502Phase 2

The Role of Contrast Enhanced Ultrasound in Appendicitis

Completed
NCT03295656Phase 1

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5